Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
75°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
23Andme Holding Co.
(NQ:
ME
)
0.3234
+0.0131 (+4.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 23Andme Holding Co.
< Previous
1
2
3
4
5
6
7
8
9
Next >
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy
February 05, 2024
Invitae's financial challenges as it grapples with a $1.5 billion debt burden. Explore the company's strategic options amidst potential bankruptcy, asset shedding, and cost-cutting measures.
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Troubled Biotech Company's Investigational Cancer Drug Gets Greenlighted By FDA
January 31, 2024
This development marks a significant milestone for 23andMe, a company that has been in the spotlight for security breaches in the past.
Via
Benzinga
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
January 31, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
January 30, 2024
“Seat 16” program allows audiences to share the critically acclaimed film with teens across the country
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Faces Class Action Lawsuit Over Alleged Privacy Breach Targeting Chinese And Ashkenazi Jewish Customers
January 27, 2024
23andMe faces a class-action lawsuit for a privacy breach affecting 7 million customers, particularly Chinese and Ashkenazi Jewish customers.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
23andMe to Report FY2024 Third Quarter Financial Results
January 24, 2024
From
23andMe, Inc.
Via
GlobeNewswire
The 3 Worst Stock Investments I Ever Made -- and What I Learned From Them
January 21, 2024
Not all of my investments have been winners. Here are three that went badly and the important lessons I learned from them.
Via
The Motley Fool
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
December 19, 2023
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Reveals Hackers Accessed 'Significant Number' Of DNA Records
December 02, 2023
23andMe confirmed that hackers accessed around 14,000 customer accounts and an undisclosed number of files containing users' ancestry data.
Via
Benzinga
Topics
Hacking
Exposures
Information Security
The 3 Best Digital Health Stocks for Personalized Medicine
November 25, 2023
Digital health stocks are becoming increasingly relevant as more and more people seek greater control over their health.
Via
InvestorPlace
23andMe Reports Second Quarter Fiscal 2024 Financial Results
November 08, 2023
Announced launch of new 23andMe+ Total Health™ membership, signed new $20M non-exclusive data license with GSK, continued progress on improving product margin
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership
November 07, 2023
The Company’s first-of-its-kind health membership combines exome sequencing, blood testing and direct access to clinicians trained in genetics for ongoing disease prevention and early detection
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
November 06, 2023
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data
October 31, 2023
23andMe+ members will receive customized action plans, from recommended lifestyle changes to clinician-ordered lab tests through 23andMe
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
October 30, 2023
Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe...
From
23andMe, Inc.
Via
GlobeNewswire
23andMe to Report FY2024 Second Quarter Financial Results
October 25, 2023
From
23andMe, Inc.
Via
GlobeNewswire
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
October 23, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
The Top 7 Stocks to Own During a Downturn
October 11, 2023
Investors tend to get jittery in October but these seven stocks to own during a downturn will protect your portfolio
Via
InvestorPlace
23andMe Under Siege: Hacker Reportedly Steals Millions Of Profiles In Genetic Data Heist
October 07, 2023
An unidentified hacker reportedly claims to have stolen personal genetic data from millions of 23andMe Holding Co. (NASDAQ: ME) customer accounts, sparking concerns over privacy and security.
Via
Benzinga
Topics
Hacking
Exposures
Information Security
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
September 27, 2023
23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignancies
From
23andMe, Inc.
Via
GlobeNewswire
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
September 14, 2023
From
23andMe, Inc.
Via
GlobeNewswire
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
September 11, 2023
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care....
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Top 5 Health Care Stocks That May Explode In Q3
September 06, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Why Olin Are Trading Lower By 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 01, 2023
Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) surged 181.1% to $3.63. TradeUP Acquisition Corp. (NASDAQ: UPTD) gained 148.5% to $18.14.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
September 01, 2023
Via
Benzinga
Why Dell Technologies Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
September 01, 2023
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) rose 53.4% to $0.2147 in pre-market trading after the company announced it received an Underwriting Clearance Notice for a $70 million coupon.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
August 31, 2023
Via
Benzinga
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
August 31, 2023
From
23andMe, Inc.
Via
GlobeNewswire
Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe
August 25, 2023
Both businesses have a lot to prove.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Why 23andMe Holding Stock Plummeted by 13% Today
August 09, 2023
Investors reacted sharply and not well to the company's inaugural set of fiscal 2024 earnings.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.